A novel and safe protocol for patients with severe comorbidity who undergo haploidentical hematopoietic stem cell transplantation: A single-center prospective study
This study suggested that a novel conditioning regimen followed by haploidentical HSCT might be a promising option for patients with severe comorbidities. The study was registered as a clinical trial (NCT03412409).
Authors
- Xiao‐Jun Huang (ORCID: https://orcid.org/0000-0002-2145-6643)
- Feng‐Rong Wang (ORCID: https://orcid.org/0000-0001-6778-1962)
- Xiao‐Dong Mo (ORCID: https://orcid.org/0000-0002-9881-7945)
- Kai‐Yan Liu (ORCID: https://orcid.org/0000-0002-6751-7827)
- Xiao Hui Zhang (ORCID: https://orcid.org/0000-0002-8778-595X)
- Yuanyuan Zhang (ORCID: https://orcid.org/0009-0000-1424-7774)
- Yao Chen (ORCID: https://orcid.org/0000-0002-7120-0902)
- Yu Wang (ORCID: https://orcid.org/0000-0003-1253-7465)
- Yuhong Chen (ORCID: https://orcid.org/0000-0001-6131-7595)
- Rui Ma (ORCID: https://orcid.org/0000-0003-0188-5499)
- Yun He
- Yuqian Sun (ORCID: https://orcid.org/0000-0003-1856-2231)
- Wei Han (ORCID: https://orcid.org/0000-0003-0809-5465)
- Wei Sun (ORCID: https://orcid.org/0000-0003-1416-3313)
- Huan Chen (ORCID: https://orcid.org/0000-0001-8648-1631)
- Lanping Xu
- Chen-Hua Yan
Institutions
- Peking University (CN)
- Peking University People's Hospital (CN)
- Center for Life Sciences (CN)
Publication Details
- Journal
- Journal of Translational Internal Medicine
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1515/jtim-2025-0018
- Citations
- 5
- Primary Topic
- Hematopoietic Stem Cell Transplantation
- Type
- article
- Field-Weighted Citation Impact
- 8.85
Funders
- National Natural Science Foundation of China
- National Key Research and Development Program of China